Department of Pathology Microbiology and Immunology

Jeffrey Rathmell, PhD, and Melissa Wolf, PhD. (photo by Susan Urmy)

Study reveals potential new way to stop a common kidney cancer

Vanderbilt researchers have identified cancer cell-specific genetic alterations that reprogram the immune “landscape,” thereby driving tumor growth, and discovered a potential new drug target for stopping it.

Mariana Byndloss, DVM, PhD

Mariana Byndloss receives FASEB Excellence in Science Award

The annual awards highlight outstanding achievements by women in the biological sciences.

From left, Jennifer Pietenpol, PhD, Eric Farber-Eger, Lauren LeStourgeon, MPH, Luisella Spiga, PhD, and John Kuriyan, PhD.

VUMC research staff honored for excellence in the lab, clinic

Laboratory and administrative personnel at Vanderbilt University Medical Center were honored on March 29 for research excellence during the 20th annual Research Staff Awards Ceremony.

From left, Simon Mallal, MBBS, and John Koethe, MD, MSCI. (photo by Susan Urmy)

VUMC’s John Koethe named director of the Tennessee Center for AIDS Research

John Koethe, MD, MSCI, associate professor of Medicine in the Division of Infectious Diseases at Vanderbilt University Medical Center, has been appointed director and principal investigator of the Tennessee Center for AIDS Research.

VUMC team discovers antibodies that may prevent severe respiratory illness

Using a technique developed at Vanderbilt University Medical Center, researchers identified antibodies that are excellent leads as potential therapies for human parainfluenza virus 3, a leading cause of acute and potentially fatal respiratory illness.

Study identifies molecule as potential target for treating AML

While immune checkpoint inhibitors that target the PD-1 molecule on T-cells have proven to be effective with many cancers, these immunotherapies have not worked for acute myeloid leukemia (AML), but new research has identified a “cousin” molecule as a potential therapeutic target for AML. 

1 2 3 30